In preclinical models for Duchenne muscular dystrophy, dystrophin restoration during adeno-associated virus (AAV)-U7-mediated exon-skipping therapy was shown to decrease drastically after six months in treated muscles. This decline in efficacy is strongly correlated with the loss of the therapeutic AAV genomes, probably due to alterations of the dystrophic myofiber membranes. To improve the membrane integrity of the dystrophic myofibers at the time of AAV-U7 injection, mdx muscles were pre-treated with a single dose of the peptide-phosphorodiamidate morpholino (PPMO) antisense oligonucleotides that induced temporary dystrophin expression at the sarcolemma. The PPMO pre-treatment allowed efficient maintenance of AAV genomes in mdx muscles and enhanced the AAV-U7 therapy effect with a ten-fold increase of the protein level after 6 months. PPMO pre-treatment was also beneficial to AAV-mediated gene therapy with transfer of micro-dystrophin cDNA into muscles. Therefore, avoiding vector genome loss after AAV injection by PPMO pre-treatment would allow efficient long-term restoration of dystrophin and the use of lower and thus safer vector doses for Duchenne patients.
Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles
Cécile Peccate, Amédée Mollard, Maëva Le Hir, Laura Julien, Graham McClorey, Susan Jarmin, Anita Le Heron, George Dickson, Sofia Benkhelifa-Ziyyat, France Piétri-Rouxel, Matthew J. Wood, Thomas Voit, Stéphanie Lorain; Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. Hum Mol Genet 2016; 25 (16): 3555-3563. doi: 10.1093/hmg/ddw201
Download citation file:
© 2017 Oxford University Press×